Ageless Biotech

Executive Summary

Ageless Biotech is a clinical-stage biopharmaceutical company focused on developing regenerative biologic therapies for osteoarthritis, leveraging adipose-derived stem cell products via Stromal Vascular Fraction (SVF) and minimally manipulated fetal tissue-based biologics. The company has received FDA approval for a Phase 2b multisite clinical trial, marking a significant milestone in its clinical development. With a strong scientific foundation targeting a large and growing osteoarthritis market, Ageless Biotech aims to address the unmet need for disease-modifying treatments. The upcoming Phase 2b trial will evaluate safety and efficacy, potentially positioning the company for further advancement and partnership opportunities. However, as a private company with limited public financials, execution risk remains, and success hinges on trial outcomes and regulatory progress.

Upcoming Catalysts (preview)

• Q3 2026Initiation of Phase 2b Multisite Clinical Trial80% success
• TBDInterim Efficacy Data Readout from Phase 2b Trial40% success
• TBDStrategic Partnership or Licensing Deal for Osteoarthritis Program30% success